How to Take Resveratrol: Dosage, Timing, and Duration

Resveratrol earned its fame from red wine and longevity headlines, but the human evidence is far more modest than the marketing suggests. If you still want to try it, the details matter: which form you buy, how much you take, whether you take it with food, and how long you stay on it. Our editorial team pulled together what clinical research actually supports.

What resveratrol is and why it is hard to absorb

Resveratrol is a polyphenol of the stilbene family that plants produce in response to stress, injury or fungal attack. In the diet it appears in grape skins, red wine, peanuts, blueberries and cranberries, but always in small amounts. Most supplements sold in the United States are made from the root of Japanese knotweed (Polygonum cuspidatum), which is a far richer source than grapes.

The molecule exists in two shapes, trans and cis. The trans form is the one used in nearly all clinical trials, so labels that state "trans-resveratrol" and its exact amount per capsule are easier to interpret. A product listing only "knotweed extract" without a standardized percentage leaves you guessing how much active compound you are getting.

The central practical problem is bioavailability. Resveratrol is absorbed reasonably well from the gut, but the liver and intestinal wall convert most of it into glucuronide and sulfate conjugates within minutes. Pharmacokinetic work by Walle and colleagues showed that after an oral dose, only trace amounts of unchanged resveratrol reach the bloodstream, even though total absorption appears to be high.

Whether those metabolites are active, and whether tissues can convert them back into free resveratrol, is still debated. This uncertainty explains why animal results, often obtained with very high doses, translate poorly to people. It also explains why manufacturers experiment with micronized powders, liposomal products and combinations with piperine or quercetin.

Doses used in human research

Clinical studies have used an unusually wide range of doses, from around 10 mg per day to 5 g per day. Lower amounts, roughly 150–500 mg, dominate the cardiometabolic research, while gram-level doses were mainly tested in early cancer-prevention and pharmacokinetic studies. More is not obviously better: higher doses raise the rate of digestive side effects without a clear gain in benefit.

A frequently cited trial by Timmers and colleagues gave obese but otherwise healthy men 150 mg per day for 30 days and reported changes in metabolic markers resembling mild calorie restriction. Other trials in people with type 2 diabetes, however, found little effect on glucose control, and meta-analyses describe results as inconsistent and dependent on dose, population and study length.

For a healthy adult trying resveratrol as a general wellness supplement, the evidence supports staying in the low-to-moderate range. A reasonable approach is to start at the lower end, assess tolerance for two weeks, and only then decide whether a higher dose is worth it. Doubling the dose is unlikely to compensate for poor absorption.

Athletes should know that resveratrol does not reliably improve performance. A small trial in older men by Gliemann and colleagues even found that 250 mg daily blunted some cardiovascular benefits of exercise training, which suggests that heavy antioxidant supplementation may interfere with training adaptations.

Timing: with meals, morning or evening

Food slows the absorption of resveratrol and modestly lowers its peak concentration, but it does not substantially reduce total exposure. In practice, taking it with a meal is usually recommended because it reduces stomach upset, and a meal containing some fat may help with fat-soluble formulations.

There is no solid evidence that morning dosing is better than evening dosing for health outcomes. Some people prefer the morning to pair it with other supplements, while others link it to dinner to remember it daily. Consistency matters more than the clock.

If you train regularly and care about adaptations, consider keeping resveratrol away from the hours right after workouts. This is a precautionary suggestion based on the antioxidant-interference hypothesis rather than a proven rule, but it costs nothing to follow.

• Take it with a meal to limit nausea or loose stools.
• Split doses above about 500 mg into two intakes.
• Pick a fixed time of day and stick with it.
• Separate it from the immediate post-workout window if training adaptations are your priority.

How long to take it

Most clinical trials last between four weeks and six months, with a few running for a year or longer. That means there is reasonable safety data for moderate doses over several months, but much less information on use measured in years.

Because resveratrol does not produce noticeable acute effects, people often judge it by how they feel, which is unreliable. If your goal is a measurable marker such as fasting glucose, blood pressure or lipids, check that marker before starting and again after about three months. No change is a reasonable signal to stop.

Some users cycle resveratrol, for example eight to twelve weeks on followed by a break. There is no physiological evidence that cycling is required, but periodic breaks are a sensible way to reassess whether the product is doing anything for you.

Long-term use is not recommended without medical oversight for people with chronic disease, because resveratrol can modestly affect platelet function and liver enzymes involved in drug metabolism.

Safety, interactions and who should skip it

At doses up to about 1 g per day, resveratrol is generally well tolerated in healthy adults. The most common complaints are digestive: diarrhea, abdominal cramps and nausea, which become more frequent above 2 g per day. Isolated reports of liver enzyme elevations have been described at high doses.

In the United States, resveratrol is sold as a dietary supplement under DSHEA rules. The FDA does not approve supplements for effectiveness before they reach the market, so quality depends on the manufacturer. Look for third-party testing seals such as USP, NSF or Informed Choice, which confirm identity and the absence of common contaminants.

Resveratrol has mild antiplatelet effects and may inhibit certain cytochrome P450 enzymes. People taking anticoagulants such as warfarin, antiplatelet drugs, or medications with a narrow therapeutic window should speak with a physician or pharmacist first. It is also wise to stop it around two weeks before planned surgery.

Because resveratrol has weak estrogen-like activity in laboratory studies, people with hormone-sensitive conditions should be cautious. Pregnant and breastfeeding women should avoid it, as safety data are lacking.

Editorial team conclusions

Resveratrol is a biologically interesting compound with a weaker human evidence base than its reputation implies. If you choose to take it, a moderate daily dose of trans-resveratrol with a meal, tested for a few months against a measurable goal, is the most rational approach.

High doses mainly add side effects, and the poor bioavailability of standard forms means expectations should stay realistic. Physically active people may want to avoid timing it around workouts.

Quality is a real issue in an unregulated market, so a third-party certified product is worth the extra cost.

For related reading, see our editorial guides on quercetin and other polyphenols, on how antioxidants interact with training adaptations, and on reading supplement labels in the United States.

References

1. Walle T, Hsieh F, DeLegge MH, Oatis JE Jr, Walle UK. High absorption but very low bioavailability of oral resveratrol in humans. Drug Metab Dispos. 2004;32(12):1377–1382.
2. Timmers S, Konings E, Bilet L, et al. Calorie restriction-like effects of 30 days of resveratrol supplementation on energy metabolism and metabolic profile in obese humans. Cell Metab. 2011;14(5):612–622.
3. Gliemann L, Schmidt JF, Olesen J, et al. Resveratrol blunts the positive effects of exercise training on cardiovascular health in aged men. J Physiol. 2013;591(20):5047–5059.
4. Brown VA, Patel KR, Viskaduraki M, et al. Repeat dose study of the cancer chemopreventive agent resveratrol in healthy volunteers: safety, pharmacokinetics, and effect on the insulin-like growth factor axis. Cancer Res. 2010;70(22):9003–9011.
5. Baur JA, Sinclair DA. Therapeutic potential of resveratrol: the in vivo evidence. Nat Rev Drug Discov. 2006;5(6):493–506.
6. Berman AY, Motechin RA, Wiesenfeld MY, Holz MK. The therapeutic potential of resveratrol: a review of clinical trials. NPJ Precis Oncol. 2017;1:35.